Juniper Publishers: Confidence Intervals for Relative Risk by Likeliho...

Juniper Publishers: Confidence Intervals for Relative Risk by Likeliho...: Biostatisticsand Biometrics Open Access Journal Juniper Publishers Authored by  Mai Zhou* Abstract In a recent article in this...

Comments

Post a Comment

Popular posts from this blog

Is Juniper Publishers Legit in 2025? A Transparent Review for Researchers

  In 2025, the academic publishing landscape continues to evolve rapidly. With the rise of open-access publishing, researchers now have more opportunities than ever to share their findings globally. Among the publishers frequently discussed in this space is Juniper Publishers — often associated with accessibility, faster publication timelines, and international reach. But an important question many researchers ask is: Is Juniper Publishers legitimate in 2025? This transparent review examines what the publisher offers, what researchers typically look for, and whether it may align with your academic publishing goals. Juniper Publishers in 2025: An Overview As of 2025, Juniper Publishers remains an active open-access academic publisher serving researchers across scientific, medical, and interdisciplinary fields. Many authors choose Juniper for several practical reasons, including: Faster editorial and peer-review timelines A user-friendly manuscript subm...
Read more

Studies on Glucagon Receptor and Antagonists of Glucagon Receptor for the Management of Diabetes Mellitus

Image
  CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL   JUNIPER PUBLISHERS Authored by Ghulam Abbas Abstract Glucagon receptor plays an important role in the glucose homeostasis and thus is drug target for the management of hyperglycemia in type-2 diabetes mellitus. The suppression of glucagon secretion from the alpha-cells is the key to control hyperglycemic condition. The identification of non-peptide antagonists of glucagon receptor is an effective therapeutic approach to inhibit the glucagon secretion to achieve normal glucose index. Keywords:  Glucagon receptor; Hyperglycemia; Diabetes mellitus; Antagonists Go to Introduction Background Diabetes mellitus is a chronic metabolic disorder which is spreading at an alarming rate all over the world. Glucagon receptor belongs to the G protein-coupled receptors (GPCRs) superfamily and an important drug target for type-2 diabetes [1]. G-Proteins (guanine nucleotide binding proteins) actually act as molecular switches to turn o...
Read more

Patient Retention Stewardship in Real world Evidence Studies: the Pentad of P's Model

Image
CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL JUNIPER PUBLISHERS Authored by Amit Kumar Abstract Real World Evidence (RWE) studies generate data that helps fill the knowledge gap between clinical trials and actual clinical practice setting. RWE studies generate data across different age groups, races, ethnicities, varying severities, unstudied co-morbid conditions, differing concomitant drugs (including OTC medications), lifestyle variations and differing adherence/compliance patterns. RWE studies are across very large number of patients and therefore may help unearth rarer ADRs which are not evident in relatively smaller populations in clinical trials. By definition the RWE studies are across larger and more diverse populations than the more controlled setting of Clinical trials which are conducted across a relatively smaller number of subjects. Given that controls are lesser in real world setting of actual practice, it is difficult to enr...
Read more